Tekla Life Sciences Investors Declares Distribution, Payable on March 31, 2021

abrdn Life Sciences Investors (the Fund), formerly Tekla Life Sciences Investors, is a non-diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in United States and foreign companies in the life sciences industry, including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies, and agriculture and environmental management. The Fund invests primarily in securities of public and private companies, which have the potential for above-average growth. The Fund invests up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of United States issuers that are traded primarily in foreign markets. The Fund's investment adviser is abrdn Inc.